<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00784459</url>
  </required_header>
  <id_info>
    <org_study_id>08-0405</org_study_id>
    <nct_id>NCT00784459</nct_id>
  </id_info>
  <brief_title>The Effect of Inhibition of B7-mediated Costimulation on Allergic Airway Inflammation in Mild Atopic Asthmatics</brief_title>
  <acronym>CIA</acronym>
  <official_title>Costimulation Inhibition in Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to determine if treatment with abatacept is effective in decreasing&#xD;
      allergic airway inflammation in mild, atopic asthmatics. Subjects will be recruited from the&#xD;
      greater St Louis Metropolitan area. Eligible individuals will undergo a titrated skin prick&#xD;
      test. Following baseline evaluation, fiberoptic bronchoscopy with segmental allergen&#xD;
      challenge (SAC) will be performed. The subjects will be randomized to either placebo or&#xD;
      abatacept. After 12 weeks of study drug, the subjects will undergo repeat SAC. The primary&#xD;
      endpoint will be to determine if treatment with abatacept results in a 50% or greater&#xD;
      decrease in the percentage of eosinophils recovered in the bronchoalveolar lavage (BAL) fluid&#xD;
      following SAC as compared to placebo control. Secondary endpoints include measures of airway&#xD;
      obstruction and hyperreactivity, airway inflammation and symptoms as well as determination of&#xD;
      the safety of abatacept administration in this subject population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      please see summary&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline Percentage of Eosinophils Recovered in the BAL Prior to Segmental Allergen Challenge</measure>
    <time_frame>baseline</time_frame>
    <description>collected prior to randomization to abatacept or placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Eosinophils Recovered Following Segmental Allergen Challenge Following 3 Months of Placebo or Abatacept</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Atopic Asthma</condition>
  <arm_group>
    <arm_group_label>Treatment with Abatacept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of Abatacept intravenously 10 mg/kg every 2 weeks for 3 doses, followed by every 4 weeks for 2 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of placebo (normal saline) intravenously 10 mg/kg every 2 weeks for 3 doses, followed by every 4 weeks for 2 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abatacept</intervention_name>
    <description>Treatment with abatacept, 10 mg/kg IV, for 5 doses.</description>
    <arm_group_label>Treatment with Abatacept</arm_group_label>
    <other_name>Orencia</other_name>
    <other_name>CTLA4Ig</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Treatment with Placebo, IV</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must meet all of the following criteria:&#xD;
&#xD;
          1. 18 - 50 years of age;&#xD;
&#xD;
          2. Previously documented physician-diagnosis of asthma consistent with NAEPP guidelines,&#xD;
             with alternative diagnoses (eg, chronic obstructive pulmonary disease) ruled out;&#xD;
&#xD;
          3. Forced expiratory volume in one second (FEV1) ≥ 70% of predicted value at screening&#xD;
             and at first SAC visit;&#xD;
&#xD;
          4. Positive methacholine inhalation challenge test of (PC20) ≤ 8 mg/mL within 6 months or&#xD;
             at screening visit;&#xD;
&#xD;
          5. History of atopic symptoms by subject self-report (allergic rhinitis, conjunctivitis,&#xD;
             or eczema);&#xD;
&#xD;
          6. A positive skin prick or intradermal test to cat allergen extract, short ragweed&#xD;
             allergen extract, or dust mite allergen extracts at screening visit. A positive skin&#xD;
             test is defined as induration of skin test wheal being ≥ 2 mm greater in diameter than&#xD;
             saline control skin wheal;&#xD;
&#xD;
          7. After the baseline SAC (V3), subject should demonstrate at least a 50% increase in the&#xD;
             percentage of eosinophils (compared to pre-allergen saline) and at least 10%&#xD;
             eosinophils in post allergen lavage.&#xD;
&#xD;
          8. Stable asthma as reflected by no significant changes in controller asthma medications,&#xD;
             no acute asthma exacerbations requiring oral corticosteroids, hospitalizations,&#xD;
             emergency room visits, or unscheduled health care provider visits for asthma for at&#xD;
             least 4 weeks prior to screening and up through the time of the first dose of study&#xD;
             drug;&#xD;
&#xD;
          9. No history of intubation for asthma;&#xD;
&#xD;
         10. Sexually active women of childbearing potential must use an effective method of birth&#xD;
             control during the entire course of the study and for 10 weeks after the final dose of&#xD;
             the study drug, in a manner such that risk of failure is minimized. Prior to study&#xD;
             enrollment, women of childbearing potential (WOCBP) will be advised of the importance&#xD;
             of avoiding pregnancy during trial participation and the potential risk factors for an&#xD;
             unintentional pregnancy. All WOCBP MUST have a negative pregnancy test on the day of&#xD;
             drug administration prior to receiving each dose. If the pregnancy test is positive,&#xD;
             the patient must not receive investigational product and must not be enrolled in the&#xD;
             study. In addition, all WOCBP should be instructed to contact the Investigator&#xD;
             immediately if they suspect they might be pregnant (e.g., missed or late menstrual&#xD;
             period) at any time during study participation.&#xD;
&#xD;
         11. Ability to give informed consent (adults must be able to consent for themselves and be&#xD;
             literate) and to comply with study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients must have none of the following:&#xD;
&#xD;
          1. Lung disease other than allergic asthma (eg, chronic bronchitis, COPD);&#xD;
&#xD;
          2. Use of chronic oral corticosteroids or inhaled corticosteroids at doses &gt; 440 μg/da&#xD;
             fluticasone or equivalent within four weeks prior to screening visit&#xD;
&#xD;
          3. Concurrent diseases, finding on physical examination, or screening laboratory studies&#xD;
             that, in the investigator's opinion, would interfere with participation in the study&#xD;
             or that might put the participant at risk by participating;&#xD;
&#xD;
          4. Upper or lower respiratory tract infections within 4 weeks before screening;&#xD;
&#xD;
          5. No febrile illness (&gt;38.0o C or 100.4oF) within 24 hours at screening and through the&#xD;
             time of the study drug administration on Study Day 0;&#xD;
&#xD;
          6. Current use of any β-adrenergic antagonist (eg, propranolol)&#xD;
&#xD;
          7. Use of long acting beta-agonists (LABA) or long acting muscarinic antagonists (LAMA)&#xD;
             within 2 weeks of screening visit.&#xD;
&#xD;
          8. Use of theophylline preparations.&#xD;
&#xD;
          9. Current allergy immunotherapy within 3 months of screening.&#xD;
&#xD;
         10. Use of systemic immunosuppressive drugs including systemic corticosteroids ,within the&#xD;
             4 weeks prior to screening up through administration of study drug;&#xD;
&#xD;
         11. Use of any TNFα inhibitor within 12 weeks of administration of study drug.&#xD;
&#xD;
         12. Participation in an intervention research study within past 4 weeks or receipt of any&#xD;
             investigational drug or biologic(s) within 5 half-lives of the agent prior to the&#xD;
             first dose of study drug and through Study Day 154;&#xD;
&#xD;
         13. Evidence of infection with hepatitis B or C virus, or human immunodeficiency virus-1&#xD;
             or 2 (HIV-1 or HIV-2), or active infection with hepatitis A;&#xD;
&#xD;
         14. History of cancer other than basal cell carcinoma or cervical carcinoma-in-situ that&#xD;
             has been treated and cured by conization or other techniques.&#xD;
&#xD;
         15. History of primary immunodeficiency;&#xD;
&#xD;
         16. History of use of tobacco products of more than one cigarette per month or equivalent&#xD;
             within 1 year prior to screening or history of smoking of greater than or equal to 10&#xD;
             pack-years;&#xD;
&#xD;
         17. History of a positive PPD;&#xD;
&#xD;
         18. History of allergic reaction to abatacept or any of the components of the study drug.&#xD;
&#xD;
         19. Pregnancy, women that are breast feeding, or that have an intention to become pregnant&#xD;
             or breast feed during the time frame of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Green, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Parulekar AD, Boomer JS, Patterson BM, Yin-Declue H, Deppong CM, Wilson BS, Jarjour NN, Castro M, Green JM. A randomized controlled trial to evaluate inhibition of T-cell costimulation in allergen-induced airway inflammation. Am J Respir Crit Care Med. 2013 Mar 1;187(5):494-501. doi: 10.1164/rccm.201207-1205OC. Epub 2013 Jan 4.</citation>
    <PMID>23292882</PMID>
  </results_reference>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>November 3, 2008</study_first_submitted>
  <study_first_submitted_qc>November 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2008</study_first_posted>
  <results_first_submitted>June 11, 2013</results_first_submitted>
  <results_first_submitted_qc>December 16, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 5, 2014</results_first_posted>
  <last_update_submitted>December 16, 2013</last_update_submitted>
  <last_update_submitted_qc>December 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jonathan Green, MD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Allergy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>recruited from asthma patient subject registry</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo : Treatment with Placebo, IV</description>
        </group>
        <group group_id="P2">
          <title>Treatment With Abatacept</title>
          <description>abatacept : Treatment with abatacept, 10 mg/kg IV, for 5 doses.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo : Treatment with Placebo, IV</description>
        </group>
        <group group_id="B2">
          <title>Treatment With Abatacept</title>
          <description>abatacept : Treatment with abatacept, 10 mg/kg IV, for 5 doses.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" spread="7.8"/>
                    <measurement group_id="B2" value="35" spread="9.8"/>
                    <measurement group_id="B3" value="31" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Baseline Percentage of Eosinophils Recovered in the BAL Prior to Segmental Allergen Challenge</title>
        <description>collected prior to randomization to abatacept or placebo</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo : Treatment with Placebo, IV</description>
          </group>
          <group group_id="O2">
            <title>Treatment With Abatacept</title>
            <description>abatacept : Treatment with abatacept, 10 mg/kg IV, for 5 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Percentage of Eosinophils Recovered in the BAL Prior to Segmental Allergen Challenge</title>
          <description>collected prior to randomization to abatacept or placebo</description>
          <units>percentage of cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" spread="30"/>
                    <measurement group_id="O2" value="19" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Eosinophils Recovered Following Segmental Allergen Challenge Following 3 Months of Placebo or Abatacept</title>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo : Treatment with Placebo, IV</description>
          </group>
          <group group_id="O2">
            <title>Treatment With Abatacept</title>
            <description>abatacept : Treatment with abatacept, 10 mg/kg IV, for 5 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Eosinophils Recovered Following Segmental Allergen Challenge Following 3 Months of Placebo or Abatacept</title>
          <units>percentage of cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" spread="28"/>
                    <measurement group_id="O2" value="17" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo : Treatment with Placebo, IV</description>
        </group>
        <group group_id="E2">
          <title>Treatment With Abatacept</title>
          <description>abatacept : Treatment with abatacept, 10 mg/kg IV, for 5 doses.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Jonathan Green</name_or_title>
      <organization>Washington University</organization>
      <phone>314-747-3591</phone>
      <email>jgreen@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

